TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01524445

Intervention type: OTHER
Intervention: bortezomib retreatment due to relapse
Description: Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
Study: NCT01924546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
Study: NCT03606252

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
Study: NCT03850067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT03606252

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

Intervention type: OTHER
Group type: OTHER
Intervention: urine sampling
Description: 2 urine sample (1 at J0 and 1 at J7)

Intervention type: OTHER
Group type: OTHER
Intervention: urine sampling
Description: 2 urine sample (1 at J0 and 1 at J7)

Intervention type: OTHER
Group type: OTHER
Intervention: urine sampling
Description: 2 urine sample (1 at J0 and 1 at J7)
Study: NCT03885726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Flow Plus
Description: High velocity nasal insufflation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Conventional therapy per institution
Study: NCT02034357

Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive function
Description: Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep evaluations
Description: Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
Study: NCT04078152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion q4w with 1500mg durvalumab until progressive disease
Study: NCT03223090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tool-use
Description: Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand
Description: Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
Study: NCT03757481

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
Study: NCT02519244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso® (Wearable lower limb exoskeleton)
Description: The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
Study: NCT04757779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib hydrochloride combined with irinotecan or docetaxel
Description: From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
Study: NCT04478682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application
Description: Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
Study: NCT01883440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose oxidase + glucose
Description: Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline+glucose
Description: Placebo arm
Study: NCT01064453

Intervention type: DRUG
Intervention: E2/DRSP (Angeliq, BAY86-4891)
Description: Take one tablet daily, continuously
Study: NCT00035425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: 600mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: 1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
Study: NCT01661400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Study: NCT03189524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
Study: NCT03314363

Intervention type: DRUG
Group type: OTHER
Intervention: double ultrafiltration
Description: double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under citrate predilution and double ultrafiltration rate
Description: repeat blood gas analysis of blood on different sample points and dialysis fluid

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: pause and restart nutritional therapy
Description: pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: evolution of vitamin and trace elements
Description: blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
Study: NCT01525576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster
Description: 3 week booster program + 2 additional weeks two months later for follow-up.
Study: NCT02183246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfiromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT04455971

Intervention type: BEHAVIORAL
Intervention: Orgasmic Meditation
Description: Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
Study: NCT04619550

Intervention type: OTHER
Group type: OTHER
Intervention: High tibial osteotomy
Description: Realignment surgery
Study: NCT01075061

Intervention type: OTHER
Group type: OTHER
Intervention: healthy volunteers
Description: morphological and functional brain MRI; transcranial magnetic stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Kallmann
Description: morphological and functional brain MRI; transcranial magnetic stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Congenital Mirror Movement
Description: morphological and functional brain MRI; transcranial magnetic stimulation
Study: NCT04540718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna
Description: 15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
Study: NCT01560884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 1500 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 3000 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 4500 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 6000 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
Study: NCT05247333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minor ailment service
Description: The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
Study: NCT01661400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study: NCT05565261

Intervention type: DEVICE
Intervention: complete denture
Description: Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.

Intervention type: DEVICE
Intervention: complete denture
Description: Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
Study: NCT04421989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Coaching
Description: Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
Study: NCT02885350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal analgesia for labour pain
Description: Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
Study: NCT02720445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal Patch
Description: 21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Matching placebo patches worn during waking hours.
Study: NCT03999424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous human Schwann cells
Description: Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
Study: NCT02885350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal analgesia for labour pain
Description: Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia for labour pain
Description: Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia for labour pain
Description: Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
Study: NCT00392678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Salsalate
Study: NCT00336232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: phylloquinone (vitamin K1) 500 mcg daily in third month
Study: NCT00640029

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: * posterior,~* anterior,~* circumference approach
Study: NCT03288272

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiotherapy
Description: Radiotherapy of the whole brain

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiotherapy
Description: Radiotherapy of the whole brain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care including nutrition, pain medication, steroids as needed
Study: NCT00640029

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: * posterior,~* anterior,~* circumference approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)
Description: * SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)
Description: * SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)
Description: * SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®
Study: NCT00086840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00940342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: 250 mcg injection under the skin, three times a week for eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: 250 mcg injection under the skin, three times a week for eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: 250 mcg injection under the skin, three times a week for eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly for four weeks
Study: NCT01540188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Intervention to Address Drug Use and HIV in Vietnam
Description: Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community
Study: NCT03866863

Intervention type: OTHER
Intervention: Intrauterine growth restriction (IUGR)
Description: Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
Study: NCT02028104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
Study: NCT02500199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
Study: NCT00488618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine (RGH-188)
Description: Cariprazine 3 mg - 12 mg oral administration, once per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo oral administration, once per day.
Study: NCT03887559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based stabilization and skill training in addition to individual treatment
Description: Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual: conventional individual treatment (outpatient). Not standardized.
Study: NCT02256865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole is taken 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole is taken 4 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone is taken 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone is taken 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone gel is applied once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Testosterone gel is applied once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ketoconazole
Description: Placebo for ketoconazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ketoconazole
Description: Placebo for ketoconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for hydrocortisone
Description: Placebo for hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for hydrocortisone
Description: Placebo for hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for testosterone
Description: Placebo for testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for testosterone
Description: Placebo for testosterone